Gsk (GLAXF) Change in Acquisitions & Divestments (2016 - 2026)

Gsk's Change in Acquisitions & Divestments history runs 11 years deep, the most recent figure standing at -$505.6 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 18.76% year-over-year to -$505.6 million; the TTM figure through Mar 2026 stood at -$524.3 million (down 17.5% YoY), while the FY2025 annual figure was -$1.8 billion, down 11.08% from the prior year.
• Change in Acquisitions & Divestments was -$505.6 million for Q1 2026 at Gsk, down from -$8.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $219.3 million in Q4 2022 to a low of -$505.6 million in Q1 2026.
• Historically, Change in Acquisitions & Divestments has averaged -$110.2 million across 5 years, with a median of -$7.4 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments surged 242.73% in 2022, then tumbled 106.22% in 2023.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $219.3 million in 2022, then sank by 106.22% to -$13.7 million in 2023, then gained by 24.79% to -$10.3 million in 2024, then gained by 22.27% to -$8.0 million in 2025, then tumbled by 6234.63% to -$505.6 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at -$505.6 million (Q1 2026), -$8.0 million (Q4 2025), and -$6.7 million (Q3 2025), per Business Quant data.